Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 9Gynecologic 5Breast 4Genitourinary 1

Conditions

Breast Neoplasms 69Triple Negative Breast Neoplasms 32Ovarian Neoplasms 21Neoplasm Metastasis 10Prostatic Neoplasms 8Pancreatic Neoplasms 7Fanconi Anemia, Complementation Group D1 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Advanced Breast Cancer 4Recurrence 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Inflammatory Breast Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms, Castration-Resistant 1Primary Myelofibrosis 1Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian 1

Interventions

olaparib 4Carboplatin 2talazoparib 1pembrolizumab 1Surveys and Questionnaires 1Paclitaxel 1Genotype 1Genetic Counseling 1Demography 1Data Collection 1Counseling 1Cognitive Behavioral Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × olaparib × Breast × Clear all
NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Beth Israel Deaconess Medical Center

Phase 2 Active not recruiting
114 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Okayama University

Phase 2 Recruiting
23 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

AstraZeneca

Phase 2 Completed
54 enrolled 17 charts
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT02418624 2019-01-16

REVIVAL

The Netherlands Cancer Institute

Phase 1 Completed
25 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡